Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ (@kidneycancerj) 's Twitter Profile
Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ

@kidneycancerj

An International, Scientific, Peer-reviewed Journal (ISSN 1933-0863) for latest advances & quality research in Kidney Cancers published by BioMedzGlobal.com

ID: 1191556936778633223

linkhttps://www.kidney-cancer-journal.com/ calendar_today05-11-2019 03:25:02

913 Tweet

1,1K Followers

4,4K Following

Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

Update on #COSMIC313 trial presented by the one and only Laurence Albiges: C+N+I showed sustained PFS & ORR benefits over P+N+I in 1L intermediate/poor risk pts. OS was similar between arms (HR 1.02). Addition of Cabo to N+I overcomes M2-like macrophage-mediated immune suppression

Update on #COSMIC313 trial presented by the one and only <a href="/AlbigesL/">Laurence Albiges</a>: C+N+I showed sustained PFS &amp; ORR benefits over P+N+I in 1L intermediate/poor risk pts. OS was similar between arms (HR 1.02). 
Addition of Cabo to N+I overcomes M2-like macrophage-mediated immune suppression
Cristiane D Bergerot (@crisbergerot) 's Twitter Profile Photo

Updated clinical outcomes from the phase I study on cabozantinib (cabo) + nivolumab (nivo) with or without CBM588 in metastatic RCC patients! 📊🔬 New insights into combination therapy for better outcomes ASCO #GU25 Hedyeh Ebrahimi Sumanta K. Pal, MD, FASCO

Updated clinical outcomes from the phase I study on cabozantinib (cabo) + nivolumab (nivo) with or without CBM588 in metastatic RCC patients! 📊🔬 New insights into combination therapy for better outcomes <a href="/ASCO/">ASCO</a> #GU25 <a href="/EbrahimiHedyeh/">Hedyeh Ebrahimi</a> <a href="/montypal/">Sumanta K. Pal, MD, FASCO</a>
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

New kid on the block! Toni Choueiri, MD HIF-2α Inhibitor Cas in ccRCC: Early Promise! -Active across IMDC risk groups in pretreated ccRCC. -Grade 3 anemia (36%) & hypoxia (6-9%), no Grade ≥4 TEAEs. -Next: PEAK-1 (Cas + Cabo) & first-line IO combo trials! #GU25 @asco @oncoalert

New kid on the block! <a href="/DrChoueiri/">Toni Choueiri, MD</a> 
HIF-2α Inhibitor Cas in ccRCC: Early Promise!
-Active across IMDC risk groups in pretreated ccRCC.
-Grade 3 anemia (36%) &amp; hypoxia (6-9%), no Grade ≥4 TEAEs.
-Next: PEAK-1 (Cas + Cabo) &amp; first-line IO combo trials! #GU25 @asco @oncoalert
Rana McKay, MD, FASCO (@drranamckay) 's Twitter Profile Photo

Excellent updated data from Cosmic 313. Positive PFS but no difference in OS. Many lessons learned. Transcriptomic work demonstrated tumors with high M2 macrophages derived benefit. Laurence Albiges Toni Choueiri, MD #GU25

Excellent updated data from Cosmic 313. Positive PFS but no difference in OS. Many lessons learned. Transcriptomic work demonstrated tumors with high M2 macrophages derived benefit. <a href="/AlbigesL/">Laurence Albiges</a> <a href="/DrChoueiri/">Toni Choueiri, MD</a> #GU25
Tom Powles (@tompowles1) 's Twitter Profile Photo

SAMETA: the 1st biomarker driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET driven group looks promising for durva/savolitinib. drfrankiejs also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?

SAMETA: the 1st biomarker driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET driven group looks promising for durva/savolitinib.  <a href="/drfrankiejs/">drfrankiejs</a> also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?
Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo

Another nice slide by Maite Bourlon . Useful in clinics. Time off systemic therapy for major surgical intervention in advanced RCC . Note that Cabozantinib Needs to stop 3 weeks before surgery and Lenvatinib needs to stop one week before surgery. ASCO #GU25.

Another nice slide by <a href="/BourlonMaite/">Maite Bourlon</a> . Useful in clinics. Time off systemic therapy for major surgical intervention in advanced RCC . Note that Cabozantinib Needs to stop 3 weeks before surgery and Lenvatinib needs to stop one week before surgery.  <a href="/ASCO/">ASCO</a> #GU25.
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

🎉Thrilled to support AACR Scholars-in-Training Dr. Xiaofan Lu & Dr. Emily Arner, with Chris Johnson Foundation Inc.. Thanks to all the fellow #kidneycancer supporting orgs and congrats to all the 2025 awardees! #aacr25 #cancerresearchsaveslives

🎉Thrilled to support <a href="/AACR/">AACR</a> Scholars-in-Training Dr. Xiaofan Lu &amp; Dr. Emily Arner, with <a href="/renalmedullary/">Chris Johnson Foundation Inc.</a>. Thanks to all the fellow #kidneycancer supporting orgs and congrats to all the 2025 awardees! #aacr25 #cancerresearchsaveslives
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Brilliant work from Cristiane D Bergerot (mentored by Tom Powles) to introduce a novel #HRQOL metric for #kidneycancer. This one is different, folks! There are separate, short components of this that can be used for #localized & #metastatic dz (see “Scoring Document”). Developed with a

Brilliant work from <a href="/crisbergerot/">Cristiane D Bergerot</a> (mentored by <a href="/tompowles1/">Tom Powles</a>) to introduce a novel #HRQOL metric for #kidneycancer. This one is different, folks! There are separate, short components of this that can be used for #localized &amp; #metastatic dz (see “Scoring Document”). Developed with a
Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

So pleased to share research highlights from our #IKCSNA24 mtg marking ✨25 yrs✨ of the KCA's work to gather the scientific community! Find in-depth articles, editorials, and personal perspectives from leading #kidneycancer experts at Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ: kidney-cancer-journal.com/IKCSNA-Proc.php

So pleased to share research highlights from our #IKCSNA24 mtg marking ✨25 yrs✨ of the KCA's work to gather the scientific community! Find in-depth articles, editorials, and personal perspectives from leading #kidneycancer experts at <a href="/KidneyCancerJ/">Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ</a>: kidney-cancer-journal.com/IKCSNA-Proc.php
ASCO (@asco) 's Twitter Profile Photo

Psst ... want to see how we're brewing up #ASCO25? We're busy behind the scenes making sure everything's just right! Can't WAIT to officially open the doors, welcome everyone, and get this Annual Meeting party started! See you there!

ASCO (@asco) 's Twitter Profile Photo

Welcome to #ASCO25! The energy is electric as we kick off a week of scientific discovery, breakthroughs, and inspiring connections. Get ready to dive deep into oncology advancements and shape the future of cancer care. We're thrilled you're here!